Emerging as a promising advance in the battle against obesity, Retatrutide is capturing considerable buzz. This treatment combines properties of two established GLP-1 receptor agonists, semaglutide , plus an unique glucose-dependent peptide component. Preliminary patient findings have demonstrated substantial weight loss in patients with a high BMI